Amlodipine Cost in Vermont 2026: Cash Price, Medicaid, Insurance, and Compounding

What Does Amlodipine Actually Cost in Vermont in 2026?

Generic amlodipine tablets are among the most affordable prescription drugs available in Vermont. The average cash-pay price at Vermont retail pharmacies sits at approximately $8 per month for a 30-day supply of 5 mg tablets in 2026. Brand-name Norvasc carries a manufacturer list price near $80 per month, though almost no cash-paying patient needs to pay that figure given the wide availability of generics and discount programs.

Amlodipine is a dihydropyridine calcium channel blocker approved by the FDA in 1992 for hypertension and chronic stable angina [1]. Because it has been off-patent since 2007, multiple generic manufacturers compete for market share, and that competition is what keeps the Vermont cash price so low.

Price does vary by pharmacy. A 30-tablet supply of generic amlodipine 5 mg has been documented at the following approximate cash prices at major Vermont-accessible chains in 2026:

• Walmart (Rx Program): ~$4 per 30 tablets
• Costco Pharmacy: ~$5 per 30 tablets
• CVS (without discount card): ~$15 to $22 per 30 tablets
• Walgreens (without discount card): ~$14 to $20 per 30 tablets
• Independent Vermont pharmacies: $8 to $12 on average

Using a free GoodRx coupon at participating pharmacies routinely brings the price to $4 to $9 per 30 tablets regardless of chain [2]. The FDA's own drug-competition data confirm that entry of four or more generic manufacturers typically reduces brand prices by more than 80 percent, which is exactly what happened with amlodipine [3].

The clinical rationale for amlodipine's widespread use is strong. In the ASCOT-BPLA trial (N=19,257 patients with hypertension), an amlodipine-based regimen reduced the primary endpoint of nonfatal myocardial infarction and fatal coronary heart disease by 10 percent compared with an atenolol-based regimen over a median 5.5 years, a result that reached statistical significance at P<0.0001 [4]. Guidelines from the American Heart Association and American College of Cardiology list amlodipine as a first-line agent for hypertension in most adult populations [5].

Vermont Medicaid Coverage for Amlodipine

Vermont Medicaid (Green Mountain Care) covers amlodipine, but a prior authorization (PA) request is required before the claim will process. The PA requirement reflects formulary tier placement, not a determination that amlodipine is medically inappropriate. Vermont's Medicaid program follows the federal requirement that state Medicaid formularies cover at least one drug per therapeutic class, and calcium channel blockers satisfy that requirement [6].

Steps to obtain PA under Vermont Medicaid in 2026:

1. Your prescriber submits a PA request to Vermont Department of Vermont Health Access (DVHA) through the state's ePACES portal or by fax.
2. DVHA typically responds within 24 to 72 hours for standard requests and within 24 hours for urgent requests.
3. Once approved, coverage applies for the approved period, usually 12 months before renewal.

Vermont Medicaid's preferred drug list (PDL) for cardiovascular agents is updated quarterly [7]. Patients enrolled in a Vermont Medicaid Managed Care Organization (MCO) such as Medicaid through the Green Mountain Care Board may face slightly different tier criteria, so confirming with your specific plan is worth the phone call.

The 2022 ACC/AHA Guideline on Hypertension states: "Thiazide diuretics, CCBs, ACE inhibitors, and ARBs are recommended as first-line therapy for most patients with hypertension" [5]. That guideline language directly supports PA approval for amlodipine in virtually any hypertensive Medicaid enrollee who has not tolerated first-line diuretics.

Low-income Vermonters who do not qualify for Medicaid but earn under 300 percent of the federal poverty level may access reduced-cost drugs through the Vermont Chronic Care Initiative (VCCI), which coordinates medication access alongside disease management [8].

Is Compounded Amlodipine Legal in Vermont?

Yes. Vermont law permits compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act to prepare patient-specific amlodipine formulations. A 503A pharmacy compounds drugs for an individual patient based on a valid prescription from a licensed prescriber. Vermont's Board of Pharmacy licenses and inspects these pharmacies under state rules that align with USP Chapter 795 standards for non-sterile compounding [9].

Compounded amlodipine has clinical applications when commercially manufactured tablets are not suitable. Common scenarios include:

• Pediatric patients requiring a liquid suspension (no FDA-approved pediatric oral liquid exists for amlodipine) [10]
• Patients with swallowing difficulties who need a reformulated dosage form
• Individuals with tablet-binder allergies to excipients in commercial generics

Cost of compounded amlodipine in Vermont varies by pharmacy and formulation. In some telehealth-plus-pharmacy arrangements, the compounded product may be provided at no direct cost to the patient when bundled with a subscription service. Stand-alone compounding pharmacy pricing for a 30-day oral suspension supply typically runs $30 to $60 before any discount.

The FDA has not placed amlodipine on its "Demonstrably Difficult to Compound" list, which means 503A pharmacies may compound it freely [11]. The agency has also not designated amlodipine as a "drug that is essentially a copy" of a commercially available product in any formal guidance applicable to individual-patient 503A compounding. Prescribers and patients should confirm that their chosen Vermont compounding pharmacy holds a current Vermont Board of Pharmacy license before filling.

The HealthRX 503A Compounding Decision Framework for Amlodipine in Vermont:

| Clinical Need | Recommended Pathway | Estimated Vermont Cost | |---|---|---| | Standard hypertension, able to swallow tablets | Generic tablet at retail pharmacy | ~$8/month cash | | Pediatric dosing or dysphagia | 503A compounded oral suspension | $30 to $60/month | | Medicaid patient, all dose forms | Medicaid PA pathway (tablet) | $0 to $3 copay | | Telehealth bundled service | Provider-arranged compounding | May be $0 bundled |

Amlodipine Insurance Coverage in Vermont

Most private health insurance plans sold in Vermont through the Green Mountain Care Board exchange and through employer-sponsored coverage tier generic amlodipine as a Tier 1 (preferred generic) drug. A Tier 1 copay in Vermont typically ranges from $0 to $10 per 30-day fill depending on the plan design [12].

Vermont follows ACA-compliant plan rules, which prohibit insurers from excluding coverage for drugs used to treat covered conditions such as hypertension. Because hypertension is not a preexisting condition exclusion under the ACA, insurers cannot deny amlodipine claims on coverage-exclusion grounds [13].

Key insurance scenarios in Vermont 2026:

Employer-sponsored plans. Most large-employer plans in Vermont (covering state employees through the Vermont State Employees' Health Plan and private employers) list generic amlodipine as a Tier 1 drug with a $0 to $5 copay. Patients on high-deductible health plans (HDHPs) may pay the full negotiated price, typically $8 to $14, until the deductible is met.

Individual and family plans through Vermont Health Connect. Formulary tiers differ across carriers. Blue Cross Blue Shield of Vermont and MVP Health Care, the two dominant carriers in Vermont's individual market, both list amlodipine as Tier 1 generics on their 2025 to 2026 formularies.

Medicare Part D in Vermont. Generic amlodipine is covered under virtually all Part D plans operating in Vermont. The 2024 Medicare Drug Price Negotiation provisions under the Inflation Reduction Act do not apply to amlodipine because it is already generic and competitively priced [14]. Standard Tier 1 Part D copays for amlodipine run $0 to $7 per month depending on the specific plan.

The American Heart Association's 2023 blood pressure guideline update reaffirmed that "achieving blood pressure control requires access to affordable medications," directly supporting insurer coverage obligations for antihypertensives like amlodipine [15].

How to Get the Cheapest Amlodipine in Vermont

Several concrete pathways exist to minimize out-of-pocket cost.

GoodRx and similar discount platforms. GoodRx, RxSaver, and Blink Health negotiate cash prices below standard retail rates at most Vermont pharmacies. GoodRx prices for generic amlodipine 5 mg (30 tablets) range from $4 to $9 at participating Vermont locations as of mid-2025 [2]. These coupons cannot be combined with Medicaid or Medicare Part D, but they often beat the copay on some commercial insurance tiers.

Walmart $4 Prescription Program. Walmart's generic drug list includes amlodipine 5 mg and 10 mg at $4 per 30-day supply. Vermont has multiple Walmart Pharmacy locations, including Burlington, Rutland, Barre, and St. Albans. No membership is required to access this pricing [16].

Pfizer Patient Assistance. Pfizer, the manufacturer of brand-name Norvasc, offers the Pfizer Patient Assistance Program for uninsured or underinsured patients who meet income criteria. Eligible Vermont residents may receive brand-name Norvasc at no cost. Applications are submitted through Pfizer's RxPathways portal [17]. Given that generics cost $4 to $8, most Vermont patients have no financial reason to seek brand Norvasc, but the program exists for those with specific formulary or clinical reasons.

Vermont Rx Connect. Vermont operates a pharmaceutical assistance referral service that connects residents to manufacturer patient assistance programs, state pharmacy assistance, and federal programs. Residents can reach it through the Vermont Department of Health's chronic disease resources page [8].

Mail-order pharmacy. A 90-day mail-order supply of generic amlodipine typically costs $10 to $24 through major pharmacy benefit managers, reducing per-dose cost by 20 to 40 percent compared with monthly retail fills. Vermont residents covered by Blue Cross Blue Shield of Vermont can access Prime Therapeutics mail-order pharmacy for 90-day supplies.

Telehealth Prescribing of Amlodipine in Vermont

Vermont allows telehealth prescribing of amlodipine. A Vermont-licensed physician, NP, or PA may evaluate a patient via synchronous audio-video telehealth and issue an amlodipine prescription without an in-person visit, provided the prescriber establishes an appropriate patient-provider relationship under Vermont's telehealth statutes (18 V.S.A. Chapter 43) [18].

Vermont's telehealth parity law requires that commercial insurers reimburse telehealth services at the same rate as equivalent in-person services. That parity extends to the prescribing encounter, meaning a telehealth hypertension visit that results in an amlodipine prescription carries the same coverage as an office visit. Vermont Medicaid also covers synchronous telehealth visits for medication management [19].

Amlodipine is not a controlled substance. It carries no DEA scheduling, so the Ryan Haight Act's in-person examination requirement does not apply. A qualifying audio-video encounter is sufficient for an initial prescription in Vermont.

For patients using HealthRX or similar telehealth platforms, blood pressure monitoring at home with a validated upper-arm cuff device is standard. The ACC/AHA recommends home blood pressure monitoring as a complement to office measurements for diagnosing and managing hypertension [5]. Devices validated by the American Medical Association's Blood Pressure Validated Device Listing are preferred [20].

Amlodipine's long half-life (30 to 50 hours) makes it forgiving of occasional missed doses and suitable for telehealth-managed patients who check in monthly or quarterly rather than weekly [1]. Steady-state plasma concentration is reached within 7 to 8 days of consistent dosing, which is relevant for telehealth follow-up timing: schedule the first follow-up call no earlier than 10 days after initiation to assess blood pressure response accurately.

Amlodipine Dosing, Efficacy, and Side-Effect Profile Relevant to Vermont Patients

The FDA-approved dosing range for hypertension is 2.5 mg to 10 mg once daily for adults [1]. Older adults and patients with hepatic impairment should begin at 2.5 mg. Dose escalation may occur after 7 to 14 days based on blood pressure response.

Efficacy data are compelling. The ALLHAT trial (N=33,357), the largest antihypertensive outcome trial conducted to date, found that amlodipine (as the CCB arm) was non-inferior to chlorthalidone for the primary composite of fatal coronary heart disease and nonfatal MI, with a 6-year event rate of 11.3 percent vs. 11.5 percent for the diuretic arm (P=0.65) [21]. ALLHAT also demonstrated that amlodipine produced fewer cases of new-onset diabetes compared with chlorthalidone (9.8 percent vs. 11.6 percent, P<0.001), a clinically relevant finding for Vermont's population given the state's rising type 2 diabetes prevalence reported by the CDC [22].

ASCOT-BPLA (N=19,257) specifically compared an amlodipine-based regimen against atenolol-based therapy and found statistically significant reductions in total cardiovascular events and procedures (HR 0.84 to 95% CI 0.78 to 0.90, P<0.0001) favoring amlodipine [4]. The trial was stopped early because of superiority of the amlodipine arm.

Common adverse effects include peripheral edema (7 to 10 percent of patients at 10 mg), flushing, and headache [1]. Edema is dose-dependent and may be attenuated by combining amlodipine with an ACE inhibitor or ARB, a strategy endorsed by the 2022 ACC/AHA guideline [5]. The drug is generally well-tolerated in patients with chronic kidney disease and does not require dose adjustment for renal impairment, which is relevant given Vermont's aging rural population [23].

Amlodipine does not significantly interact with most common medications, but concurrent use with simvastatin above 20 mg per day increases simvastatin exposure via CYP3A4 inhibition, raising myopathy risk. The FDA issued a specific safety communication on this interaction [24]. Patients in Vermont who are prescribed both drugs should have simvastatin capped at 20 mg per day or switched to an alternative statin.

Vermont-Specific Cost Reduction Checklist

For Vermont prescribers and patients, this checklist summarizes the fastest route to minimal amlodipine cost:

1. Confirm generic is dispensed. Ask the pharmacist to verify the dispensed product is a generic (INN: amlodipine besylate or amlodipine maleate). Brand substitution without request adds cost with no clinical benefit.
2. Check Walmart $4 program first. For uninsured patients within driving distance of a Vermont Walmart, this is the single lowest cash-pay option.
3. Apply a GoodRx coupon at other chains. Free to use; download GoodRx or NeedyMeds app before arriving at the pharmacy.
4. Verify Medicaid PA is on file before the pharmacy submits. A rejected claim without PA delays treatment. Prescribers should submit PA paperwork at the time of the prescription.
5. Request 90-day supply on commercial insurance. Mail-order reduces copays per dose and minimizes pharmacy trips, particularly relevant for Vermont's rural patients.
6. Ask about 503A compounding only when standard tablets are clinically inadequate. Compounding adds regulatory steps and may cost more unless bundled with a telehealth program.

Vermont residents without any coverage should know: at $4 to $8 per month, generic amlodipine cash pricing is low enough that filing an insurance claim may not save money once copays, deductibles, and formulary tiers are factored in. A direct cash purchase at Walmart or with a GoodRx coupon often costs less than Tier 2 or Tier 3 copays.